Chase Investment Counsel Corp Has $536,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Chase Investment Counsel Corp lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 510 shares of the biopharmaceutical company’s stock after selling 97 shares during the period. Chase Investment Counsel Corp’s holdings in Regeneron Pharmaceuticals were worth $536,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. International Assets Investment Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after buying an additional 879,916 shares during the period. Capital International Investors lifted its holdings in shares of Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after purchasing an additional 213,038 shares during the period. Price T Rowe Associates Inc. MD raised its position in Regeneron Pharmaceuticals by 25.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after purchasing an additional 184,561 shares during the last quarter. Swedbank AB acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth about $129,257,000. Finally, Epoch Investment Partners Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $99,667,000. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on REGN shares. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Piper Sandler reduced their price objective on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Wells Fargo & Company lowered their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, October 22nd. JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Finally, Oppenheimer lowered their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,107.25.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.6 %

NASDAQ:REGN opened at $821.00 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $784.96 and a 12 month high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm’s 50 day moving average is $1,007.57 and its 200 day moving average is $1,037.30. The stock has a market capitalization of $90.22 billion, a PE ratio of 20.32, a price-to-earnings-growth ratio of 3.12 and a beta of 0.15.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.